Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis

The Lancet Haematology

Volumn 2, Issue 5, 2015, Pages e194-e203

  Admiraal, Rick ^a,b,c   van Kesteren, Charlotte ^a,c   Jol van der Zijde, Cornelia M ^b   Lankester, Arjan C ^b   Bierings, Marc B ^a   Egberts, Toine C G ^a   van Tol, Maarten J D ^b   Knibbe, Catherijne A J ^c,d   Bredius, Robbert G M ^b   Boelens, Jaap J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LEIDEN UNIVERSITY   (Netherlands)

^d ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CLEMASTINE; METHOTREXATE; MYCOPHENOLATE MOFETIL; PREDNISOLONE; THYMOCYTE ANTIBODY; LYMPHOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; CD4+ T LYMPHOCYTE; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL OUTCOME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; FEMALE; GRAFT FAILURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE RESPONSE; INFANT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOID LEUKEMIA; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ALLOTRANSPLANTATION; CLINICAL TRIAL; CYTOLOGY; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; MULTICENTER STUDY; PRESCHOOL CHILD; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ANTILYMPHOCYTE SERUM; CD4-POSITIVE T-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84929052072     PISSN: None     EISSN: 23523026     Source Type: Journal    
DOI: 10.1016/S2352-3026(15)00045-9     Document Type: Article

References (32)

1. Mohty, M, Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 21 (2007), 1387–1394.
2. Lindemans, CA, Chiesa, R, Amrolia, PJ, et al. Impact of Thymoglobulin prior to pediatric unrelated umbilical cord blood transplantation on immune reconstitution and clinical outcome. Blood 123 (2014), 126–132.
3. Szabolcs, P, Niedzwiecki, D, Immune reconstitution after unrelated cord blood transplantation. Cytotherapy 9 (2007), 111–122.
4. Theurich, S, Fischmann, H, Chemnitz, J, Holtick, U, Scheid, C, Skoetz, N, Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults. Cochrane Database Syst Rev, 9, 2012 CD009159.
5. Mohty, M, Labopin, M, Balère, ML, et al. Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Sociéte Française de Greffe de Moelle et de Thérapie Cellulaire. Leukemia 24 (2010), 1867–1874.
6. Hiwarkar, P, Gaspar, HB, Gilmour, K, et al. Impact of viral reactivations in the era of pre-emptive antiviral drug therapy following allogeneic haematopoietic SCT in paediatric recipients. Bone Marrow Transplant 48 (2013), 803–808.
7. Bartelink, IH, Belitser, SV, Knibbe, CA, et al. Immune reconstitution kinetics as an early predictor for mortality using various hematopoietic stem cell sources in children. Biol Blood Marrow Transplant 19 (2013), 305–313.
8. Seidel, MG, Fritsch, G, Matthes-Martin, S, et al. Antithymocyte globulin pharmacokinetics in pediatric patients after hematopoietic stem cell transplantation. J Pediatr Hematol Oncol 27 (2005), 532–536.
9. Remberger, M, Persson, M, Mattsson, J, Gustafsson, B, Uhlin, M, Effects of different serum-levels of ATG after unrelated donor umbilical cord blood transplantation. Transpl Immunol 27 (2012), 59–62.
10. Call, SK, Kasow, KA, Barfield, R, et al. Total and active rabbit antithymocyte globulin (rATG; thymoglobulin) pharmacokinetics in pediatric patients undergoing unrelated donor bone marrow transplantation. Biol Blood Marrow Transplant 15 (2009), 274–278.
11. Waller, EK, Langston, AA, Lonial, S, et al. Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant 9 (2003), 460–471.
12. Jol-van der Zijde, C, Bredius, R, Jansen-Hoogendijk, A, et al. IgG antibodies to ATG early after pediatric hematopoietic SCT increase the risk of acute GvHD. Bone Marrow Transplant 47 (2012), 360–368.
13. Bosch, M, Dhadda, M, Hoegh-Petersen, M, et al. Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation. Cytotherapy 14 (2012), 1258–1275.
14. Servais, S, Lengline, E, Porcher, R, et al. Long-term immune reconstitution and infection burden after mismatched hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 20 (2014), 507–517.
15. Jacobson, CA, Turki, A, McDonough, S, et al. Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 18 (2012), 565–574.
16. Admiraal, R, van Kesteren, C, Jol-van der Zijde, C, et al. Population pharmacokinetic modeling of thymoglobulin® in children receiving allogeneic-hematopoietic cell transplantation (HCT): towards improved survival through individualized dosing. Clin Pharmacokinet 54 (2015), 435–446.
17. Bartelink, IH, Boelens, JJ, Bredius, RGM, et al. Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing. Clin Pharmacokinet 51 (2012), 331–345.
18. Bartelink, IH, Bredius, RGM, Belitser, SV, et al. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation. Biol Blood Marrow Transplant 15 (2009), 231–241.
19. Booth, C, Veys, P, T cell depletion in paediatric stem cell transplantation. Clin Exp Immunol 172 (2013), 139–147.
20. Glucksberg, H, Storb, R, Fefer, A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18 (1974), 295–304.
21. Shulman, HM, Sullivan, KM, Weiden, PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 69 (1980), 204–217.
22. Fine, JP, Gray, RJ, A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94 (1999), 496–509.
23. Apperley, J, Carreras, E, Gluckman, E, Masszi, T, EBMT-ESH handbook on haemopoietic stem cell transplantation, 6th edn., 2012, Forum Service Editore, Genoa, Italy.
24. Gabrielsson, J, Weiner, D, Pharmacokinetic and pharmacodynamic data analysis: concepts and applications, 4th edn., 2015, Swedish Pharmaceutical Press, Stockholm.
25. Chiesa, R, Gilmour, K, Qasim, W, et al. Omission of in vivo T-cell depletion promotes rapid expansion of naive CD4+ cord blood lymphocytes and restores adaptive immunity within 2 months after unrelated cord blood transplant. Br J Haematol 156 (2012), 656–666.
26. Cohen, Y, Nagler, A, Umbilical cord blood transplantation—how, when and for whom?. Blood Rev 18 (2004), 167–179.
27. Bashir, Q, Munsell, MF, Giralt, S, et al. Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplant. Leuk Lymphoma 53 (2012), 915–919.
28. Finke, J, Bethge, WA, Schmoor, C, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 10 (2009), 855–864.
29. Na, I-K, Wittenbecher, F, Dziubianau, M, et al. Rabbit antithymocyte globulin (Thymoglobulin) impairs the thymic output of both conventional and regulatory CD4+ T cells after allogeneic hematopoietic stem cell transplantation in adult patients. Haematologica 98 (2013), 23–30.
30. Bacigalupo, A, Lamparelli, T, Bruzzi, P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 98 (2001), 2942–2947.
31. Champlin, RE, Perez, WS, Passweg, JR, et al. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood 109 (2007), 4582–4585.
32. Benjamin, J, Chhabra, S, Kohrt, HE, et al. Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms. Biol Blood Marrow Transplant 20 (2014), 837–843.